Detailed financial statements for Genprex, Inc. (GNPX): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.41, GNPX has negative trailing earnings (P/E not meaningful) and an ROE of -163.13%. Market capitalisation stands at $2M.
Balance sheet quality for GNPX: current ratio of 3.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $5885 | $13070 | $22777 | $22534 | $25575 | $15004 | $6693 | 0 |
| Gross Profit | 0 | 0 | -$5885 | -$13070 | -$22777 | -$22534 | -$25575 | -$15004 | -$6693 | 0 |
| Research & Development | $354883 | $289934 | $971427 | $2.0M | $7.3M | $9.0M | $11.5M | $17.6M | $10.5M | $9.4M |
| Selling, General & Admin | $3.8M | $3.0M | $11.4M | $8.7M | $10.6M | $11.7M | $12.3M | $13.4M | $10.6M | $6.1M |
| Operating Expenses | $4.1M | $3.3M | $12.4M | $10.7M | $17.9M | $20.6M | $23.8M | $31.1M | $21.2M | $15.5M |
| Operating Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$18.0M | -$20.7M | -$23.8M | -$31.1M | -$21.2M | -$15.5M |
| EBITDA | -$4.1M | -$3.3M | -$12.3M | -$10.6M | -$17.9M | -$20.6M | -$23.7M | -$30.8M | -$21.1M | -$15.5M |
| Interest Expense | 0 | $1890 | $37982 | 0 | 0 | 0 | 0 | 0 | 0 | $739935 |
| Pre-tax Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| Income Tax | 0 | $80 | $29184 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M |
| EPS | $-16830.00 | $-12705.00 | $-39567.00 | $-29304.00 | $-22198.00 | $-19305.00 | $-21780.00 | $-24838.00 | $-5872.98 | $-382.80 |
| EPS (Diluted) | $-16786.00 | $-12683.00 | $-39534.00 | $-29249.00 | $-22198.00 | $-19305.00 | $-21780.00 | $-24816.00 | $-5872.98 | $-382.80 |
| Shares Outstanding (Diluted) | $246 | $261 | $313 | $364 | $807 | $1070 | $1090 | $1243 | $3642 | $42397 |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth (YoY) | +19.8% | -273.3% | +13.9% | -68.4% | -15.2% | -14.9% | -30.0% | +31.6% | +23.1% | |
| EPS Growth (YoY) | +24.5% | -211.4% | +25.9% | +24.2% | +13.0% | -12.8% | -14.0% | +76.4% | +93.5% | |
| Shares Change (YoY) | +6.1% | +19.9% | +16.3% | +121.7% | +32.6% | +1.9% | +14.0% | +193.0% | +1064.1% | |
| Effective Tax Rate | -0.0% | -0.0% | -0.2% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | -163.13% |
| Return on Invested Capital | -107.08% |
| Return on Assets | -96.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 6.77 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -27.43 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -12.29 | -16.28 | -1.22 | -0.48 | -8.23 | -2.99 | -2.93 | -0.41 | -0.16 | -0.10 |
| P/B | 31.18 | 125.94 | 1.71 | 1.70 | 4.77 | 1.49 | 3.12 | 1.70 | 2.11 | 0.21 |
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: BDRX · BIVI · CERO · CMMB · CNSP · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of GNPX: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks